Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Feb;50(2):183–185. doi: 10.1136/thx.50.2.183

Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans.

R I Cargill 1, B J Lipworth 1
PMCID: PMC473921  PMID: 7701460

Abstract

BACKGROUND--Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) exhibit in vitro pulmonary vasodilator activity, but little information is available regarding their effects in the human pulmonary vasculature. Their effects in the human pulmonary circulation and their ability to modulate the pulmonary pressor effects of angiotensin II have therefore been evaluated. METHODS--Eight healthy volunteers were studied on three separate occasions. Infusions of either ANP, BNP, or placebo were given for 60 minutes with a concomitant infusion of angiotensin II given for the final 30 minutes. Pulmonary haemodynamics were measured by pulsed wave Doppler echocardiography at baseline (T0), before commencing angiotensin II (T30), and at the end of the infusion period (T60). RESULTS--Mean pulmonary artery pressure (MPAP) showed a fall with ANP and BNP infusion at T30 compared with placebo. Although angiotensin II infusion had significant pulmonary pressor effects on all three study days, MPAP at T60 was lower when ANP (18.3 (2.0) mm Hg) and BNP (16.1 (1.5) mm Hg) were given concomitantly compared with placebo (21.8 (1.6) mm Hg). CONCLUSIONS--These findings indicate that both ANP and BNP exhibit pulmonary vasorelaxant activity in humans in terms of antagonism of the pulmonary pressor effects of angiotensin II. This would support the hypothesis that ANP and BNP act as circulating counter-regulatory hormones in states of pathological pulmonary vasoconstriction.

Full text

PDF
183

Images in this article

184Image
on p.184

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnot S., Andrivet P., Chabrier P. E., Piquet J., Plas P., Braquet P., Roudot-Thoraval F., Brun-Buisson C. Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion. J Clin Invest. 1989 Mar;83(3):986–993. doi: 10.1172/JCI113985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexander J. M., Nyby M. D., Jasberg K. A. Effect of angiotensin on hypoxic pulmonary vasoconstriction in isolated dog lung. J Appl Physiol. 1976 Jul;41(1):84–88. doi: 10.1152/jappl.1976.41.1.84. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. V., Struthers A. D., Payne N. N., Slater J. D., Bloom S. R. Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man. Clin Sci (Lond) 1986 May;70(5):507–512. doi: 10.1042/cs0700507. [DOI] [PubMed] [Google Scholar]
  4. Bertoli L., Lo Cicero S., Busnardo I., Rizzato G., Montanari G. Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. Respiration. 1986;49(4):251–256. doi: 10.1159/000194887. [DOI] [PubMed] [Google Scholar]
  5. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dabestani A., Mahan G., Gardin J. M., Takenaka K., Burn C., Allfie A., Henry W. L. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol. 1987 Mar 1;59(6):662–668. doi: 10.1016/0002-9149(87)91189-1. [DOI] [PubMed] [Google Scholar]
  7. Lang C. C., Coutie W. J., Struthers A. D., Dhillon D. P., Winter J. H., Lipworth B. J. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992 Nov;83(5):529–533. doi: 10.1042/cs0830529. [DOI] [PubMed] [Google Scholar]
  8. Lang C. C., Coutie W. J., Struthers A. D., Dhillon D. P., Winter J. H., Lipworth B. J. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992 Nov;83(5):529–533. doi: 10.1042/cs0830529. [DOI] [PubMed] [Google Scholar]
  9. Lipworth B. J., Dagg K. D. Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. Br J Clin Pharmacol. 1994 Mar;37(3):273–278. doi: 10.1111/j.1365-2125.1994.tb04275.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipworth B. J., Dagg K. D. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest. 1994 May;105(5):1360–1364. doi: 10.1378/chest.105.5.1360. [DOI] [PubMed] [Google Scholar]
  11. Patakas D., Georgopoulos D., Rodini H., Christaki P. Effects of captopril in patients with chronic obstructive pulmonary disease and secondary pulmonary hypertension. Postgrad Med J. 1988 Mar;64(749):193–195. doi: 10.1136/pgmj.64.749.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. SEGEL N., HARRIS P., BISHOP J. M. The effects of synthetic hypertensin of the systemic and pulmonary circulations in man. Clin Sci. 1961 Feb;20:49–61. [PubMed] [Google Scholar]
  13. Yoshimura M., Yasue H., Morita E., Sakaino N., Jougasaki M., Kurose M., Mukoyama M., Saito Y., Nakao K., Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991 Oct;84(4):1581–1588. doi: 10.1161/01.cir.84.4.1581. [DOI] [PubMed] [Google Scholar]
  14. Zhao L., Hughes J. M., Winter R. J. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1198–1201. doi: 10.1164/ajrccm/146.5_Pt_1.1198. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES